Australia's largest stock trading and investment forum Australia's #1 stock forum

VLA

Click for more information

0.00%

$1.75 viralytics limited

IDO1/Keytruda combo trial fails in melanoma, page-12

First 12 Last

Share
Profile

Follow
Lopez

3,253 Posts.

26

09/04/18

11:07

Post #: 32313733
Share

Originally posted by Shellbell ↑

Hi Davie I take on board wholeheartedly your opinion based on the fact you presented... the fact that the failed Incyte/Merck combo was a riskier punt. Well lets hope you are right that "VLA's long-term insto holders would be talking to Merck about whether the current offer is appropriate". An outcome from that is far more likely to be positive for the SP than shareholders knocking back the offer with a NO vote.

Given the info you shared (which is enlightening, btw), I still do not believe retail shareholders should have the attitude of voting NO to the offer (whether it be the current one or a counter one)... not that their votes will have much bearing. The worst case scenario for VLA shareholders is to end up back on the market... imo. I could be wrong, but would hate to have to test it.

Thanks, Davie, for your input. I have appreciated your insightful contributions over the years.

Expand

Hi,
something going on. IMO.
Aloha.

VLA Price at posting: $1.70 Sentiment: Buy Disclosure: Held
8 Upvote

0 Great analysis

Reply

Top Stories

HAW

Hastings links up with KSA for development of rare earths supply chain

WC8

Pan Asia rebranding to 'clear confusion' after bagging $35M for Chile projects

MIN

MinRes's Ellison knows he screwed up – for that reason, hunt for new Chair to be sped up

History-making uranium sample grades and an imminent drill run. Infini Resources is poised to transform in 2025

ACW

This biotech stock raised $11M in a risk-off environment. Its Alzheimer's drug could change the game

There are more pages in this discussion • 5 more messages in this thread...

First 12 Last

Add VLA (ASX) to my watchlist